arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Oruka Therapeutics, Inc.

ORKA Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances
$92.51
Today
as of Sep 4, 16:52 ET
Last 30 days +2.56% Jul 27 → Sep 04
$86.07 $93.32 $100.58 $107.83 $115.08 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$90.06
High
$93.98
Low
$89.75
Volume
$600,469
Avg Vol
$916,153
Mkt Cap
$6.9B
P/E (TTM)
—
Beta
—
52w High
$115.52
52w Low
$14.67
Div Yield
—
Shares Out
$61M

Recent Press Releases & News last 60 days · 8 items

Aug 28 · 15:10 Zacks
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Aug 24 · 20:14 MT Newswires
Oruka Therapeutics Names Chief Commercial Officer
Aug 24 · 20:01 PR GlobeNewswire
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
▸ Show all 8 press releases & news Free account →

Overview

52-week range
$15
$116
77% of range
Avg surprise (last 3)
+13.9%
Avg reaction (last 2)
-0.7%
50% positive
Latest IV / EM
90%
EM ±14.0% · $95 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-6.96$-5.25$-3.53$-1.81$-0.10 Actual $-0.10Actual $-0.10Actual $-0.14Actual $-6.96Actual $-1.46Actual $-0.40Est $-0.57Actual $-0.46Est $-0.48Actual $-0.48Est $-0.52 JunSepMarJunSepMar/2025Jun/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-41M$-36M$-32M$-27M$-22M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed May 13, 2026Mar/2026 $-0.48 $-0.52 +7.7% -20.0% -2.3% earnings
Mon Aug 11, 2025Jun/2025 $-0.46 $-0.48 +4.2% — — earnings
Wed May 14, 2025Mar/2025 $-0.40 $-0.57 +29.8% — +0.9% earnings
Mon Sep 30, 2024Sep 2024 $-1.46 — — — — financials
Sun Jun 30, 2024Jun 2024 $-6.96 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.14 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.10 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.10 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-50M$-36M—$-34M$-28M$-25M—$-29M
Net income$-41M$-32M—$-30M$-25M$-21M—$-29M
EPS (diluted)————$-0.46$-0.40—$-1.46

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$268M$50M$47M$91M$65M$84M$62M$411M
Inventory————————
Total current assets$885M$395M$344M$355M$332M$352M$377M$413M
Total assets$1.14B$504M$489M$509M$357M$377M$396M$414M
Long-term debt————————
Total liabilities$25M$18M$17M$22M$14M$12M$14M$19M
Total equity$1.11B$487M$472M$487M$344M$365M$382M$342M

Implied volatility — last 90 days

71%88%106%123%141% Jun 07 — IV 76% · EM ±10.5%Jun 08 — IV 101% · EM ±13.4%Jun 09 — IV 77% · EM ±9.7%Jun 10 — IV 84% · EM ±10.0%Jun 11 — IV 73% · EM ±8.1%Jun 12 — IV 74% · EM ±7.6%Jun 15 — IV 81% · EM ±5.8%Jun 16 — IV 118% · EM ±6.9%Jun 17 — IV 141% · EM ±5.9%Jun 19 — IV 88% · EM ±19.5%Jun 22 — IV 99% · EM ±20.6%Jun 23 — IV 98% · EM ±20.0%Jun 24 — IV 97% · EM ±19.4%Jun 25 — IV 95% · EM ±18.7%Jun 26 — IV 97% · EM ±18.6%Jun 29 — IV 101% · EM ±17.8%Jun 30 — IV 105% · EM ±18.1%Jul 01 — IV 109% · EM ±18.2%Jul 02 — IV 98% · EM ±15.8%Jul 03 — IV 101% · EM ±15.8%Jul 06 — IV 121% · EM ±16.8%Jul 07 — IV 130% · EM ±17.2%Jul 08 — IV 77% · EM ±9.6%Jul 09 — IV 76% · EM ±9.0%Jul 10 — IV 75% · EM ±8.2%Jul 13 — IV 71% · EM ±5.9%Jul 14 — IV 135% · EM ±9.8%Jul 15 — IV 102% · EM ±6.0%Jul 16 — IV 130% · EM ±5.4%Jul 20 — IV 90% · EM ±21.4%Jul 21 — IV 97% · EM ±22.6%Jul 22 — IV 94% · EM ±21.6%Jul 23 — IV 94% · EM ±21.2%Jul 24 — IV 95% · EM ±20.9%Jul 27 — IV 98% · EM ±20.4%Jul 28 — IV 98% · EM ±20.0%Jul 29 — IV 97% · EM ±19.4%Jul 30 — IV 111% · EM ±21.7%Jul 31 — IV 102% · EM ±19.5%Aug 03 — IV 97% · EM ±17.2%Aug 04 — IV 99% · EM ±17.1%Aug 05 — IV 90% · EM ±15.0%Aug 06 — IV 87% · EM ±14.1%Aug 07 — IV 84% · EM ±13.2%Aug 10 — IV 79% · EM ±10.9%Aug 11 — IV 85% · EM ±11.3%Aug 12 — IV 84% · EM ±10.5%Aug 13 — IV 77% · EM ±9.1%Aug 14 — IV 73% · EM ±8.0%Aug 17 — IV 92% · EM ±7.7%Aug 18 — IV 84% · EM ±6.1%Aug 19 — IV 83% · EM ±4.9%Aug 20 — IV 126% · EM ±5.3%Aug 24 — IV 88% · EM ±18.3%Aug 25 — IV 89% · EM ±18.2%Aug 26 — IV 89% · EM ±17.8%Aug 27 — IV 91% · EM ±17.8%Aug 28 — IV 87% · EM ±16.6%Aug 31 — IV 98% · EM ±17.4%Sep 01 — IV 99% · EM ±17.0%Sep 02 — IV 88% · EM ±14.8%Sep 03 — IV 88% · EM ±14.2%Sep 04 — IV 90% · EM ±14.0%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in